WEKO3
アイテム
{"_buckets": {"deposit": "879b88da-6744-4614-adcf-a5aaca9c2ba6"}, "_deposit": {"created_by": 2, "id": "14558", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "14558"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00014558", "sets": ["11"]}, "author_link": ["53493", "53491", "53492"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2008", "bibliographicIssueDateType": "Issued"}, "bibliographicPageEnd": "221", "bibliographicPageStart": "209", "bibliographic_titles": [{"bibliographic_title": "Oncogene Proteins: Structure, Functions and Analyses"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Fes (also known as Fps), together with Fer, form the nonreceptor protein tyrosine kinase subfamily. The expression of Fes in normal tissues has been shown to be limited to monocytic hematopoietic cells, endothelial cells, and some neuronal and epithelial cells. Studies using mice expressing activated mutant Fes or cultured endothelial cells indicated that Fes might be involved in pathological angiogenesis, suggesting it could be a potential target for antiangiogenic therapy. Fes was initially identified as a protooncogene product. However, recent studies have indicated that Fes may act also as a tumor suppressor protein in some carcinomas, such as colon cancer, based on the identification of inactivating mutated Fes in colon cancer tissues and downregulated expression of Fes in some cancer cells. Thus, during treatment of these cancers, inhibition of Fes activity may stimulate progression of the pathological process. In this short communication, we will review the recent reports on the roles of Fes in tumor progression and discuss the problems that must be solved before targeting of this kinase in any anti-cancer therapy.", "subitem_description_type": "Abstract"}]}, "item_2_description_5": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "Editors: Peter B. Murphy and Jason R. Clarke", "subitem_description_type": "Other"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Oncogene Proteins: Structure, Functions and Analyses, pp.209-221; 2008", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nova Science Publishers"}]}, "item_2_relation_9": {"attribute_name": "ISBN", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "978-1-60456-259-0", "subitem_relation_type_select": "ISBN"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2008 Nova Science Publishers, Inc."}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kanda, Shigeru"}], "nameIdentifiers": [{"nameIdentifier": "53491", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyata, Yasuyoshi"}], "nameIdentifiers": [{"nameIdentifier": "53492", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kanetake, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "53493", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-22"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "OncPro_209.pdf", "filesize": [{"value": "318.2 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 318200.0, "url": {"label": "OncPro_209.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/14558/files/OncPro_209.pdf"}, "version_id": "2d05bcee-9110-4fc6-bcf9-7415f357b901"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Non-receptor Protein Tyrosine Kinase Fes as a Candidate for Anticancer Molecular Targeting Therapy", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Non-receptor Protein Tyrosine Kinase Fes as a Candidate for Anticancer Molecular Targeting Therapy"}]}, "item_type_id": "2", "owner": "2", "path": ["11"], "permalink_uri": "http://hdl.handle.net/10069/24553", "pubdate": {"attribute_name": "公開日", "attribute_value": "2011-01-12"}, "publish_date": "2011-01-12", "publish_status": "0", "recid": "14558", "relation": {}, "relation_version_is_last": true, "title": ["Non-receptor Protein Tyrosine Kinase Fes as a Candidate for Anticancer Molecular Targeting Therapy"], "weko_shared_id": -1}
Non-receptor Protein Tyrosine Kinase Fes as a Candidate for Anticancer Molecular Targeting Therapy
http://hdl.handle.net/10069/24553
http://hdl.handle.net/10069/24553c5271ab8-3987-40e8-8c52-c056db578d64
名前 / ファイル | ライセンス | アクション |
---|---|---|
OncPro_209.pdf (318.2 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2011-01-12 | |||||
タイトル | ||||||
タイトル | Non-receptor Protein Tyrosine Kinase Fes as a Candidate for Anticancer Molecular Targeting Therapy | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Kanda, Shigeru
× Kanda, Shigeru× Miyata, Yasuyoshi× Kanetake, Hiroshi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Fes (also known as Fps), together with Fer, form the nonreceptor protein tyrosine kinase subfamily. The expression of Fes in normal tissues has been shown to be limited to monocytic hematopoietic cells, endothelial cells, and some neuronal and epithelial cells. Studies using mice expressing activated mutant Fes or cultured endothelial cells indicated that Fes might be involved in pathological angiogenesis, suggesting it could be a potential target for antiangiogenic therapy. Fes was initially identified as a protooncogene product. However, recent studies have indicated that Fes may act also as a tumor suppressor protein in some carcinomas, such as colon cancer, based on the identification of inactivating mutated Fes in colon cancer tissues and downregulated expression of Fes in some cancer cells. Thus, during treatment of these cancers, inhibition of Fes activity may stimulate progression of the pathological process. In this short communication, we will review the recent reports on the roles of Fes in tumor progression and discuss the problems that must be solved before targeting of this kinase in any anti-cancer therapy. | |||||
内容記述 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Editors: Peter B. Murphy and Jason R. Clarke | |||||
書誌情報 |
Oncogene Proteins: Structure, Functions and Analyses p. 209-221, 発行日 2008 |
|||||
出版者 | ||||||
出版者 | Nova Science Publishers | |||||
ISBN | ||||||
識別子タイプ | ISBN | |||||
関連識別子 | 978-1-60456-259-0 | |||||
権利 | ||||||
権利情報 | © 2008 Nova Science Publishers, Inc. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Oncogene Proteins: Structure, Functions and Analyses, pp.209-221; 2008 |